Cadrenal Therapeutics, Inc. released its financial results for the first quarter of 2026 and provided updates on the Phase III clinical trial plans for its core drug, CAD-1005.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This progress is based on the follow-up development pathway formulated after the company successfully held an end-of-Phase II clinical trial meeting with the U.S. Food and Drug Administration (FDA).
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
BNY Mellon and Citadel Securities Complete Tokenized U.S. Treasury Repo Transaction
Cointime•2026/10/13 20:54
DuPont declares quarterly dividend of $0.60 per share
Bitget•2026/10/13 20:31
IntelliCheck director Dondi Black receives 2,183 RSUs at $2.29 per share
Bitget•2026/10/13 20:23
Japanese Yen: Choppy trade after JPY-supportive comments – Scotiabank
FXStreet•2026/10/13 20:15
Crypto prices
More
Bitcoin
BTC
$83,339.16
+0.39%
Ethereum
ETH
$2,509.27
-0.38%
Tether USDt
USDT
$0.9989
+0.03%
BNB
BNB
$741.65
-0.70%
XRP
XRP
$1.37
+0.03%
USDC
USDC
$0.9998
-0.00%
Solana
SOL
$107.03
-1.45%
TRON
TRX
$0.3286
-0.34%
Hyperliquid
HYPE
$81.62
-2.27%
Zcash
ZEC
$1,219.59
-1.41%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now